Welcome to our dedicated page for Apyx Medical news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical stock.
Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Apyx Medical (NASDAQ: APYX) reported a retrospective 113‑patient study of liposuction with and without Renuvion. Adding Renuvion showed higher Body‑Q satisfaction with excess skin (87.8 vs. 73.8) and abdominal appearance (68.8 vs. 45.0), over 50% lower abdominoplasty rates (30.0% vs. 67.1%), lower revision rates (12.0% vs. 37.5%), and similar complication rates (2.5% vs. 2.7%) versus power‑assisted liposuction alone over more than 12 months of follow‑up.
Apyx Medical (Nasdaq: APYX) received expanded FDA 510(k) clearance for its AYON Body Contouring System to add power liposuction, an advanced modality using a reciprocating cannula to enhance fat removal efficiency. The company plans a limited commercial launch to refine training, utilization, and customer experience.
Apyx Medical (NASDAQ:APYX) reported Q1 2026 total revenue of $12.5 million, up 32.4% year-over-year, driven by a 36.1% increase in Surgical Aesthetics to $10.7 million. Net loss attributable to stockholders narrowed to $2.1 million (‑$0.05/share). Adjusted EBITDA loss improved to $0.3 million. Cash and cash equivalents were $31.1 million as of March 31, 2026. Management raised 2026 total revenue guidance to $59.0–$60.0 million and increased Surgical Aesthetics guidance to $54.0–$55.0 million. Apyx cited stronger international sales, including South Korea, and AYON adoption as drivers.
Apyx Medical (NASDAQ:APYX) will release first-quarter fiscal 2026 results before markets open on May 7, 2026. Management will host an 8:00 a.m. ET conference call and live webcast the same day; replay will be archived on the company’s Investor Relations website. Apyx markets Renuvion, J-Plasma, and the FDA-cleared AYON Body Contouring System; the company cites more than 90 clinical documents supporting Renuvion and J-Plasma.
Apyx Medical (NASDAQ: APYX) announced that Renuvion won the 2026 NewBeauty Award for Best Minimally Invasive Skin Tightener, marking a consecutive win and third-party recognition of its clinical impact and market position.
According to the company, Renuvion is FDA-cleared for use following liposuction and pairs with the AYON platform to broaden physician workflow and procedural options.
Apyx Medical (NASDAQ:APYX) reported Q4 2025 total revenue of $19.2M and full-year 2025 revenue of $52.8M, driven by a commercial launch of the AYON Body Contouring System in September 2025. Surgical Aesthetics revenue rose 38.1% in Q4 and 17.4% for FY2025. Q4 adjusted EBITDA was positive at $0.7M; FY2025 adjusted EBITDA loss narrowed to $3.8M. The company ended 2025 with $31.7M cash and expects FY2026 revenue of $57.5M–$58.5M and operating expenses under $45.0M. A 510(k) submission for AYON power liposuction is anticipated to be cleared mid-2026.
Apyx Medical (NASDAQ:APYX) will release fourth-quarter fiscal 2025 financial results before markets open on March 10, 2026. Management will host a conference call and webcast at 8:00 a.m. ET the same day to discuss results and take questions.
Phone dial‑in access, an international number, and an archived webcast will be available via the company’s investor relations site.
Apyx Medical (NASDAQ:APYX) said management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will take part in a fireside chat at 8:25am ET and hold investor meetings throughout the day.
The fireside chat will be available via live webcast, with a replay posted in the Events section of Apyx Medical’s Investor Relations website.
Apyx Medical (NASDAQ:APYX) said management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 in Snowbird, Utah.
Investors seeking meetings should contact their BTIG representatives. The company highlighted its Renuvion, J-Plasma, and FDA-cleared AYON Body Contouring System and noted more than 90 supporting clinical documents.
Apyx Medical (Nasdaq: APYX) reported preliminary, unaudited revenue for Q4 and full year 2025. Q4 2025 total revenue is expected to be approximately $19.0–$19.2M (+~34% YoY), driven by Surgical Aesthetics of $16.6–$16.8M (+~38% YoY) and OEM revenue of ~$2.4M (+~13% YoY). Apyx cited a U.S. Surgical Aesthetics increase of ~51% following the AYON commercial launch. For full year 2025, total revenue is expected at $52.7–$52.9M (+~10% YoY), Surgical Aesthetics $45.2–$45.4M (+~17% YoY), and OEM ~$7.5M (−21% YoY). The company will release audited results in March 2026; figures are preliminary and subject to closing and audit procedures.